Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

KMW Inc

Neither a doctor nor a teaching hospital

Research payments

$1,124,703

138 payments

Through program year 2025, KMW Inc is reported as receiving $1,124,703 in research payments, across 138 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $59 1
2024 Research $41,756 17
2023 Research $49,082 25
2022 Research $266,113 27
2021 Research $89,430 8
2020 Research $255,428 35
2019 Research $422,835 25

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $248,943 5 payments
  2. Senseonics, Incorporated $239,582 9 payments
  3. Medtronic, Inc. $232,089 62 payments
  4. Sanofi US Services Inc. $199,486 29 payments
  5. Allergan Inc. $110,223 18 payments
  6. Radius Health, Inc. $38,040 3 payments
  7. Lexicon Pharmaceuticals, Inc. $20,512 1 payment
  8. Takeda Pharmaceuticals U.S.A., Inc. $17,467 8 payments
  9. Shire North American Group Inc $13,362 2 payments
  10. Pfizer Inc. $5,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Prospective, Randomized, Double-Blind Comparison of Ly900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion $247,381 4 payments
  2. Senseonics CTP0034 PAS $121,094 4 payments
  3. PAS (Post-Approval Study to Evaluate the Safety and Effectiveness of the Eversense Continuous Glucose Monitoring (CGM) System Used Non-adjunctively) $118,488 5 payments
  4. Cip341 Impact2 $87,417 33 payments
  5. A multicenter, randomized, double-blind, dose-conversion study to evaluate the safety and efficacy of HRT w Armour Thyroid compared to levothyroxine (T4) in previously hypothyroid participants, who are on euthyroid T4 replacement $84,865 13 payments
  6. CIP336 Fiasp $84,430 13 payments
  7. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk $63,729 10 payments
  8. CIP335 Lyumjev $60,242 16 payments
  9. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular $55,022 2 payments
  10. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function $42,021 11 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record